Cargando…

Detection of IDH1 Mutations in Plasma Using BEAMing Technology in Patients with Gliomas

SIMPLE SUMMARY: In contrast with other solid tumors, only a few, small studies have shown the feasibility of detecting different biomarkers in the peripheral blood (PB) of patients with gliomas. A prospective study was conducted, enrolling 10 patients with gliomas where 33 consecutive PB samples wer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cabezas-Camarero, Santiago, García-Barberán, Vanesa, Pérez-Alfayate, Rebeca, Casado-Fariñas, Isabel, Sloane, Hillary, Jones, Frederick S., Pérez-Segura, Pedro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221506/ https://www.ncbi.nlm.nih.gov/pubmed/35740557 http://dx.doi.org/10.3390/cancers14122891

Ejemplares similares

Durable benefit and change in TCR clonality with nivolumab in a Lynch syndrome–associated glioma
por: Cabezas-Camarero, Santiago, et al.
Publicado: (2022)

Glioblastoma: an organ-confined disease?
por: Cabezas-Camarero, Santiago, et al.
Publicado: (2022)

Liquid Biopsy in Head and Neck Cancer: Current Evidence and Future Perspective on Squamous Cell, Salivary Gland, Paranasal Sinus and Nasopharyngeal Cancers
por: Cabezas-Camarero, Santiago, et al.
Publicado: (2022)

Therapies for IDH-Mutant Gliomas
por: Alshiekh Nasany, Ruham, et al.
Publicado: (2023)

Transcriptomic Correlates of Immunologic Activation in Head and Neck and Cervical Cancer
por: Saiz-Ladera, Cristina, et al.
Publicado: (2021)

The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas
por: Wang, Hao-Yuan, et al.
Publicado: (2016)

DDRE-12. HETEROGENOUS RESPONSE OF IDH-MUTANT AND IDH-WT GLIOMA TO NAMPT INHIBITION
por: Rahman, Masum, et al.
Publicado: (2021)

Immune Profiling of Gliomas Reveals a Connection with IDH1/2 Mutations, Tau Function and the Vascular Phenotype
por: Cejalvo, Teresa, et al.
Publicado: (2020)

Characteristics of gliomas in patients with somatic IDH mosaicism
por: Bonnet, Charlotte, et al.
Publicado: (2016)

Retrospective examination of pseudoprogression in IDH mutant gliomas
por: Wetzel, Ethan A, et al.
Publicado: (2023)

Stalled oligodendrocyte differentiation in IDH-mutant gliomas
por: Wei, Yanfei, et al.
Publicado: (2023)

Updates on the WHO diagnosis of IDH-mutant glioma
por: Reuss, David.E.
Publicado: (2023)

Estimation of the occurrence rates of IDH1 and IDH2 mutations in gliomas and the reconsideration of IDH-wildtype anaplastic astrocytomas: an institutional experience
por: Cho, Uiju, et al.
Publicado: (2021)

Consequences of IDH1/2 Mutations in Gliomas and an Assessment of Inhibitors Targeting Mutated IDH Proteins
por: Kaminska, Bozena, et al.
Publicado: (2019)

Methylation and transcription patterns are distinct in IDH mutant gliomas compared to other IDH mutant cancers
por: Unruh, Dusten, et al.
Publicado: (2019)

Wild-Type IDH1 and Mutant IDH1 Opposingly Regulate Podoplanin Expression in Glioma()()
por: Sun, Chao, et al.
Publicado: (2020)

CBMS-1 Targeting amino acid metabolic vulnerabilities in IDH-mutant and IDH-wildtype gliomas
por: Ohba, Shigeo, et al.
Publicado: (2021)

Isocitrate Dehydrogenase IDH1 and IDH2 Mutations in Human Cancer: Prognostic Implications for Gliomas
por: Murugan, A. K., et al.
Publicado: (2022)

Postoperative risk of IDH-mutant glioma–associated seizures and their potential management with IDH-mutant inhibitors
por: Drumm, Michael R., et al.
Publicado: (2023)

Primary bilateral fronto‐temporoparietal decompressive craniectomy—An alternative treatment for severe traumatic brain injury: Case report and technical note
por: Pérez‐Alfayate, Rebeca, et al.
Publicado: (2019)

Promoter Methylation Analysis of IDH Genes in Human Gliomas
por: Flanagan, Simon, et al.
Publicado: (2012)

Insulator dysfunction and oncogene activation in IDH mutant gliomas
por: Flavahan, William A., et al.
Publicado: (2015)

IDH1 Mutation in Gliomas in Mosul City - Iraq
por: Saeed, Mohammed Sami
Publicado: (2015)

Metabolic Reprogramming in Mutant IDH1 Glioma Cells
por: Izquierdo-Garcia, Jose L., et al.
Publicado: (2015)

Mutant IDH1 Promotes Glioma Formation In Vivo
por: Philip, Beatrice, et al.
Publicado: (2018)

Epigenetic Reprogramming for Targeting IDH-Mutant Malignant Gliomas
por: Park, Jong-Whi, et al.
Publicado: (2019)

Pharmacoresistant seizures and IDH mutation in low-grade gliomas
por: Correia, Carlos Eduardo, et al.
Publicado: (2021)

Malignant Progression of an IDH Mutant Brainstem Glioma in Adult
por: SANO, Kenshi, et al.
Publicado: (2021)

Seizures in patients with IDH-mutated lower grade gliomas
por: Carstam, Louise, et al.
Publicado: (2022)

Proteome-based insights for IDH-mutant glioma classification
por: Leu, Severina, et al.
Publicado: (2023)

Mutant IDH in Gliomas: Role in Cancer and Treatment Options
por: Solomou, Georgios, et al.
Publicado: (2023)

The efficacy of an unrestricted cycling ketogenic diet in preclinical models of IDH wild-type and IDH mutant glioma
por: Javier, Rodrigo, et al.
Publicado: (2022)

Genomic profiles of IDH-mutant gliomas: MYCN-amplified IDH-mutant astrocytoma had the worst prognosis
por: Lee, Kwanghoon, et al.
Publicado: (2023)

Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas
por: Killela, Patrick J., et al.
Publicado: (2014)

IDH1/IDH2 Mutations Define the Prognosis and Molecular Profiles of Patients with Gliomas: A Meta-Analysis
por: Zou, Peng, et al.
Publicado: (2013)

A Noninvasive Comparison Study between Human Gliomas with IDH1 and IDH2 Mutations by MR Spectroscopy
por: Shen, Xin, et al.
Publicado: (2019)

Implications of Concurrent IDH1 and IDH2 Mutations on Survival in Glioma—A Case Report and Systematic Review
por: Yuile, Alexander, et al.
Publicado: (2022)

Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent IDH1- and IDH2-mutant Glioma
por: Fanucci, Kristina, et al.
Publicado: (2023)

Transcriptional Characteristics of IDH-Wild Type Glioma Subgroups Highlight the Biological Processes Underlying Heterogeneity of IDH-Wild Type WHO Grade IV Gliomas
por: Chang, Yu-Zhou, et al.
Publicado: (2020)

A vaccine targeting mutant IDH1 in newly diagnosed glioma
por: Platten, Michael, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hlldtk7s2c2igtdo52fqpc4ikk